The life expectancy of someone diagnosed with Myeloma depends on the stage of their Myeloma, and in addition prognostic markers such as the presence of poor risk or good risk genetic abnormalities will influence the outcomes.
The diagnosis and monitoring of Myeloma during treatment has become increasingly sophisticated, and we are now able to detect presence of Myeloma at very low levels in the bone marrow (known as detecting minimal residual disease – MRD). Patients who are able to attain MRD negativity with Myeloma treatment have a significantly improved overall survival.
In general, for Myeloma patients at diagnosis, around 50% of patients will be alive and well at 5 years. However, these numbers do not factor in all variables, such as age and overall health. Additionally, treatment options for Myeloma are continuously improving. Speak to our doctor for a better understanding of the success rates of your treatment plan.













